$HIMS Q3 26 earnings - Bad numbers (but there is hope) !
Q3 2026 earnings missed on revenue, EPS, and EBITDA with a material gross margin compression (57% vs 74% prior year). However, strong international expansion (+312% YoY) and strategic board additions (Dr. Andrew Huberman) suggest potential for recovery; the company maintains its FY2030 targets of $6.5B revenue and $1.3B adjusted EBITDA, though near-term guidance was reduced.